ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Clinical Characteristics and Outcomes of Non-cancer, Non-CVC Associated upper Extremity DVT

O. Cohen1, L. Bertú1, E. Antonucci2, G. Palareti2, W. Ageno1

1Ospedale di Circolo e Fondazione Macchi, Varese, Italy, 2Arianna Foundation on Anticoagulation, Bologna, Italy

Abstract Number: PB2448

Meeting: ISTH 2020 Congress

Theme: Venous Thromboembolism and Cardioembolism » VTE Treatment

Background: Upper extremity deep venous thrombosis (UEDVT) is rare, and typically associated with cancer and central venous catheters (CVCs). Risk factors, management and outcomes of UEDVT outside the context of cancer and CVCs are not well characterized.

Aims: Compare the clinical characteristics, risk factors, management and outcomes of patients with UEDVT not associated with cancer or CVC, with those of patients with non-cancer, non-CVC associated lower extremity DVT (LEDVT) enrolled in the Survey on anticoagulaTed pAtients RegisTer (START2-Register).

Methods: The START2-Register (ClinicalTrials.gov Identifier: NCT02219984) is an observational, multicenter, prospective cohort study that includes adult patients (>18 years) who start anticoagulation therapy for various indications. Patients with cancer, history of cancer and CVCs were excluded from analysis. Of the 6,835 patients enrolled in the register, for the purpose of this analysis 2,174 patients were included for whom data were collected between September 2010 and November 2019.

Results: Eighty nine patients with UEDVT were compared with 2,085 patients with LEDVT. Patients with UEDVT were significantly younger (51.7 vs. 63.3 years, p-value< 0.0001) and were more likely to receive extended parenteral anticoagulant treatment with LMWH (6.7% vs. 1.9%, p-value=0.002). There was a trend towards preferring oral treatment with VKAs (57.3% vs. 52%, p-value=0.33) rather than with DOACs in patients with UEDVT as compared to patients with LEDVT (36% vs. 46.1%, p-value=0.06) (Table 1).
After a median follow-up of 12.2 months (IQR 5.9-25.1 months), all-cause mortality rates (incidence rate 4.6 vs. 2.5 per 100 person-years, HR 2.1, 95% CI 0.8-5.8) and arterial events rates (incidence rate 1.1 vs. 0.4 per 100 person-years, HR 3.3, 95% CI 0.4-25.5) were non-significantly higher in UEDVT patients than in LEDVT patients (Figure 1).

Conclusions: Outside the context of cancer and CVCs, patients with UEDVT are younger, and show a tendency towards higher all-cause mortality and arterial event rates than LEDVT patients.

    All patients LEDVT UEDVT P-value
N   2174 2085 89  
Follow-up (months) Median (range) 12.2 (0-75) 12.3 (0-75) 7.3 (0.2-59.3)  
Age (years) Mean (SD) 62.8 ±18.1 63.3 ±17.9 51.7 ±20.1 <0.0001
Treatment                
VKAs n (%) 1135 52.2 1084 52 51 57.3 0.33
LMWH n (%) 45 2.1 39 1.9 6 6.7 0.002
DOACs n (%) 994 45.7 962 46.1 32 36 0.06
Thrombophilia n (%) 279 12.8 267 12.8 12 13.5 0.85
Previous VTE n (%) 503 23.1 487 23.4 16 18 0.24

[Baseline characteristics of non-cancer, non-CVC patients with UEDVT vs. LEDVT enrolled in the START2-Register]


[Clinical outcomes in non-cancer, non-CVC patients with UEDVT vs. LEDVT enrolled in the START2-Register]

To cite this abstract in AMA style:

Cohen O, Bertú L, Antonucci E, Palareti G, Ageno W. Clinical Characteristics and Outcomes of Non-cancer, Non-CVC Associated upper Extremity DVT [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/clinical-characteristics-and-outcomes-of-non-cancer-non-cvc-associated-upper-extremity-dvt/. Accessed September 25, 2023.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/clinical-characteristics-and-outcomes-of-non-cancer-non-cvc-associated-upper-extremity-dvt/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley